Preexposure prophylaxis (PrEP), in which HIV-uninfected persons with ongoing HIV risk use
antiretroviral medications to reduce their risk of acquiring HIV infection, is an efficacious and …

As the global incidence of HIV exceeds 2 million new infections annually, effective
interventions to decrease HIV transmission are needed. Randomized, placebo-controlled …

Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years
where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling …

To date, six clinical trials have explored the efficacy of pre-exposure prophylaxis (PrEP)
against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged …

Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing
the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals …

Objectives: Preexposure prophylaxis (PrEP) is recommended for preventing HIV infection
among individuals at high risk, including men who have sex with men (MSM). Although its …

PrEP entails providing HIV-negative individuals with ARV drugs, and it is widely anticipated
as one of the most promising new prevention strategies. The PrEP drugs that have been …

Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably
high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis …

Importance Effective prevention strategies for HIV infection are an important public health
priority. Preexposure prophylaxis (PrEP) involves use of antiretroviral therapy (ART) daily or …

Objective: Preexposure prophylaxis (PrEP) offers a promising new approach to HIV
prevention. This systematic review and meta-analysis evaluated the evidence for use of oral …